Elsevier

The Lancet

Volume 347, Issue 8994, 13 January 1996, Pages 79-84
The Lancet

Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease

https://doi.org/10.1016/S0140-6736(96)90209-3Get rights and content

Abstract

Summary

Background Excimer laser coronary angioplasty is reported to give excellent procedural results for treatment of complex coronary lesions, but this method has not been compared with balloon angioplasty in a randomised trial.

Methods Patients (n=308) with stable angina and coronary lesions longer than 10 mm on visual assessment were included. 151 patients (158 lesions) were assigned randomly to laser angioplasty and 157 (167 lesions) to balloon angioplasty. The primary clinical endpoints were death, myocardial infarction, coronary bypass surgery, or repeat coronary angioplasty of the randomised segment during 6 months of follow-up. The primary angiographic end-point was the minimal lumen diameter at follow-up in relation to the baseline value (net gain), as determined by quantitative coronary angiography.

Findings Laser angioplasty was followed by balloon angioplasty in 98% of procedures. The angiographic success rate was 80% in patients treated with laser angioplasty compared with 79% in patients treated with balloon angioplasty. There were no deaths. Myocardial infarction, coronary bypass surgery, and repeat angioplasty occurred in 4·6%, 10·6%, and 21·2%, respectively, of the patients in the laser angioplasty group compared with 5·7%, 10·8%, and 18·5% of the balloon angioplasty group. Net mean (SD) gain in minimal lumen diameter was 0·40 (0·69) mm in patients treated with laser angioplasty and 0·48 (0·66) mm in those treated with balloon angioplasty (p=0·34). The restenosis rate (>50% diameter stenosis) was 51·6% in the laser angioplasty group versus 41·3% in the balloon angioplasty group (p=0·13).

Interpretation Excimer laser angioplasty followed by balloon angioplasty provides no benefit additional to balloon angioplasty alone with respect to the initial and long-term clinical and angiographic outcome in the treatment of obstructive coronary artery disease.

References (32)

  • C. Di Mario et al.

    Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional; atherectomy

    Am J Cardiol

    (1995)
  • Lw Klein et al.

    Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty

    J Am Coll Cardiol

    (1991)
  • Ad Kugelmass et al.

    Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting

    Am J Cardiol

    (1994)
  • M. Sartori et al.

    Tissue interactions and measurement of ablation rates with ultraviolet and visible lasers in canine and human arteries

    Lasers Surg Med

    (1987)
  • A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Guidelines for percutaneous transluminal coronary angioplasty

    Circulation

    (1988)
  • Cited by (112)

    • The Ongoing Saga of the Evolution of Percutaneous Coronary Intervention: From Balloon Angioplasty to Recent Innovations to Future Prospects

      2022, Canadian Journal of Cardiology
      Citation Excerpt :

      It was therefore perceived as a useful tool to reduce restenosis rates. However, the initial enthusiasm for this technique was blunted by observational studies that showed high rates of restenosis and complications, mostly due to the premature use of a young technology, because the first-generation coronary laser was associated with unacceptable heat production, leading to the risk of dissection and sometimes perforation.48,49 In the 1990s, technological improvements led to the introduction of excimer laser coronary angioplasty (ELCA; Philips, Amsterdam, The Netherlands), using different beams leading to less heat production and continuous saline flushing, therefore increasing safety.

    • Abrasion, grinding, pulverization, vaporization, and extraction: Debulking options for percutaneous coronary interventions of calcified coronary lesions

      2022, Debulking in Cardiovascular Interventions and Revascularization Strategies: Between a Rock and the Heart
    • Contemporary technologies to modify calcified plaque in coronary artery disease

      2021, Progress in Cardiovascular Diseases
      Citation Excerpt :

      Fourth, ELCA can vaporize thrombi,46 expanding its use in acute coronary syndromes.47 Early studies reported procedural success rates of 77–90% with ELCA,48–51 complication rates of 4–7%,51,52 restenosis rates in 46%,52 perforations in 1–2%,48,49 and in-hospital mortality of 0.5–1.5%,48,49 with no clear benefit over conventional angioplasty.50 Nevertheless, ELCA may be particularly useful compared to other forms of atherectomy in cases of venous grafts, in-stent restenosis, and treating thrombi.

    • Simple percutaneous coronary interventions using the modification of complex coronary lesion with excimer laser

      2019, Cardiovascular Revascularization Medicine
      Citation Excerpt :

      A bubble in the liquid environment results in the free ejection of debris, which is believed to be the dominant mechanism for tissue removal for ELCA (photomechanical effect) [3]. Despite these favorable effects, ELCA at the beginning showed no benefit aside from balloon angioplasty alone with respect to the initial and long-term clinical and angiographic outcomes in PCI [4]. However, several important factors that govern successful laser application have been developed to improve the efficacy and safety of ELCA.

    View all citing articles on Scopus
    View full text